Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues
This article was originally published in Pharmaceutical Approvals Monthly
FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD
You may also be interested in...
Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011